DermaPro® (CL05) is an innovative drug that is derived from dichloric acid. It is applied to poorly healing and chronic wounds by a moist wound dressing.

This wound healing therapy addresses the large unmet medical need associated with difficult to heal wounds.

Mode of action
DermaPro® carries out a dual function in supporting the body with the closure of wounds by stimulating both skin growth and disinfection.  This effective and rapid treatment includes wounds that are difficult to heal such as diabetic foot.

Clinical status – Diabetic foot ulcers

India - DermaPro received market approval (subjected to local production)

Centaur Pharmaceuticals, Mumbai, CytoTools AG’s license partner in India received market approval subjected to local production for DermaPro® ( branded as Woxheal® in India) for the treatment of diabetic foot ulcers in March 2017.

Europe – Phase III clinical trials must be repeated

The European phase III trials for the treatment of diabetic foot ulcers must be repeated.


Clinical status – Venous leg ulcers

Germany - Phase II/III study must be repeated

Clinical trials with DermaPro® for the treatment of venous leg ulcers must be repeated.